Orgenesis Inc.
ORGS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ORGS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORGS
Orgenesis Inc. is a global biotech company pioneering a decentralized, automated approach to cell and gene therapy development and manufacturing, aiming to reduce costs and accelerate market access through its POCare Network.
Key risk: Cash position and liquidity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.1M
Cash Runway
—
Lead Asset
mdvac (Preclinical)
Next Catalyst
—
Financial data as of Dec 31, 2024.
Tracking 1 pipeline candidate for Orgenesis Inc..
Orgenesis Inc. is a global biotech company pioneering a decentralized, automated approach to cell and gene therapy development and manufacturing, aiming to reduce costs and accelerate market access through its POCare Network.
- Orgenesis focuses on validating advanced production platforms for cell types, designed to deliver high-quality, regulatory-compliant cell and gene therapies through a decentralized, automated, and scalable approach [sec_mda · as of 2026-03-26].
- The company's business strategy includes out-licensing, related services, and shared revenue opportunities, targeting healthcare institutions and industry partners [sec_mda · as of 2026-03-26].
- As of December 31, 2024, Orgenesis reported cash & equivalents of $0.1M, shareholders' equity of -$21.0M, and total debt of $6.2M [sec].
- In September 2025, the company repaid $6.3 million of outstanding debt, but there is no assurance of sustainable positive cash flows to fund operations and satisfy debt obligations [sec_mda · as of 2026-03-26].
- Orgenesis in-licenses therapies to adapt them to a point-of-care approach through regional partnerships and out-licenses therapies for market approval in preferred geographical regions, lowering overall development costs [sec_mda · as of 2026-03-26].
What works
- Orgenesis's decentralized, automated production platforms aim to significantly reduce costs and time-to-market for cell and gene therapies, potentially offering a competitive advantage [sec_mda · as of 2026-03-26].
- The company's POCare Network leverages partnerships with leading hospitals and research institutes, providing deep insights into developments, market potential, and regulatory pathways [sec_mda · as of 2026-11-13].
- Orgenesis's strategy of in-licensing and out-licensing therapies through regional partnerships lowers overall development costs and can attract additional funding from grants and payments [sec_mda · as of 2026-03-26].
What to weigh
- Orgenesis has a very limited cash position of $0.1M as of December 31, 2024, and negative shareholders' equity of -$21.0M, indicating significant financial strain [sec].
- The company has an accumulated deficit and no assurance of generating sustainable positive cash flows, requiring additional financing or expense postponements to continue operations [sec_mda · as of 2026-03-26].
- Orgenesis's business model depends on out-licensing and partnerships, which may not materialize as expected, and the company faces high development costs typical of cell and gene therapies [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
Orgenesis focuses on validating advanced production platforms for cell types to deliver high-quality, regulatory-compliant cell and gene therapies.
“we have focused on validating advanced production platforms for various cell types. These platforms are designed to deliver high-quality, regulatory-compliant cell and gene therapies through a decentralized, automated, and scalable approach, significantly reducing costs and time-to-market.”
SEC MD&A · March 26, 2026
Orgenesis's business strategy includes out-licensing, related services, and shared revenue opportunities.
“Our business strategy includes out-licensing, related services and shared revenue opportunities.”
SEC MD&A · March 26, 2026
In September 2025, Orgenesis repaid $6.3 million of outstanding debt, but there is no assurance of sustainable positive cash flows.
“In September 2025, we repaid $6.3 million of this outstanding debt. Our activities have been funded by generating revenue, through offerings of our securities, and through proceeds from loans. There is no assurance that our business will generate sustainable positive cash flows to fund our business and satisfy our debt obligations.”
SEC MD&A · March 26, 2026
Risks & what to watch (4)›
Key risks
- Cash position and liquidity — Cash & equivalents of only $0.1M as of 2024-12-31, with negative equity and high debt, posing a risk of insufficient funding [sec].
- Dependence on partnerships — Business model relies on out-licensing and regional partnerships, which may not materialize or generate expected revenues [sec_mda · as of 2026-03-26].
- No sustainable positive cash flow — No assurance of generating sustainable positive cash flows; may need additional financing or expense postponements [sec_mda · as of 2026-03-26].
- High development costs — Cell and gene therapy development historically requires hundreds of millions of dollars, and Orgenesis's approach may still face significant costs [sec_mda · as of 2026-03-26].
What to watch
- Ability to secure additional financing or partnerships to extend cash runway beyond current limited resources [sec_mda · as of 2026-03-26].
- Progress in commercializing production platforms and out-licensing deals with healthcare institutions and industry partners [sec_mda · as of 2026-03-26].
- Updates on the POCare Network and any new in-licensing or out-licensing agreements that could generate revenue [sec_mda · as of 2026-11-13].
- Any clinical or regulatory milestones for therapies developed through the decentralized approach [sec_mda · as of 2026-03-26].
Sources: Competitor trials · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Orgenesis Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Orgenesis Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$17M
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 1.3%
- Days to cover
- 2.4
- Shares short
- 56,251
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORGS short interestFrequently asked questions
What is the AI investment thesis for Orgenesis Inc.?
Orgenesis Inc. is a global biotech company pioneering a decentralized, automated approach to cell and gene therapy development and manufacturing, aiming to reduce costs and accelerate market access through its POCare Network.
What is Orgenesis Inc.'s lead drug candidate?
Orgenesis Inc.'s most advanced tracked candidate is mdvac (Preclinical) for Solid Tumors.
Who is the CEO of Orgenesis Inc.?
Ms. Vered Caplan M.Sc. is the chief executive officer of Orgenesis Inc. (ORGS).
Where is Orgenesis Inc. headquartered?
Orgenesis Inc. (ORGS) is headquartered in Germantown, MD, United States.
What therapeutic areas does Orgenesis Inc. focus on?
Orgenesis Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.